Literature DB >> 17505148

Possible reasons for different pattern disappearance of thyroglobulin and thyroid peroxidase autoantibodies in patients with differentiated thyroid carcinoma following total thyroidectomy and iodine-131 ablation.

D Thomas1, V Liakos, E Vassiliou, F Hatzimarkou, A Tsatsoulis, P Kaldrimides.   

Abstract

The purpose of this study was to reveal some possible factors for the differences between the pattern of disappearance of thyroglobulin autoantibodies (anti-Tg) and thyroid peroxidase autoantibodies (anti-TPO) in patients with differentiated thyroid carcinoma following thyroidectomy and iodine-131 ablation. Patients with a history of follicular cell derived cancer (papillary, follicular, both papillary and follicular, Hürthle cell) and high pre-operative titers of anti-TPO and/or anti-Tg autoantibodies were retrospectively studied. Thyroglobulin (Tg) levels were measured using radio-immunometric assay (RIA). Anti-Tg and anti-TPO levels during the first 6 yr' follow-up were measured by passive agglutination, during the following 10 yr by ELISA method and during the last 2 yr by chemiluminescence assay. A statistically significant difference was observed between median time (72 months) of disappearance of anti-TPO and median time (39 months) of disappearance of anti-Tg in patients with complete ablation of thyroid tissue, following iodine-131 administration (p=0.0395, Logrank statistic=4.24, Kaplan-Meier method). A statistically significant difference was observed between median time (106 months) of disappearance of anti-TPO and median time (33 months) of disappearance of anti-Tg in patients >45 yr of age (p=0.034) and between median time (111 months) of disappearance of anti-TPO and median time (41 months) of disappearance of anti-Tg in patients with tumor size <2 cm (p=0.0175). We concluded that patients with differentiated thyroid carcinoma and pre-surgical elevated titers of both Tg and anti-TPO tend to become earlier anti-Tg seronegative. Although tumor size and age may influence the pattern of thyroid autoantibody reduction, the exact reasons for the different rhythm of autoantibodies decrease must further be evaluated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505148     DOI: 10.1007/BF03347421

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  32 in total

1.  Identification of an immunodominant region recognized by human autoantibodies in a three-dimensional model of thyroid peroxidase.

Authors:  P Hobby; A Gardas; R Radomski; A M McGregor; J P Banga; B J Sutton
Journal:  Endocrinology       Date:  2000-06       Impact factor: 4.736

Review 2.  Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning.

Authors:  Chao Ma; Anren Kuang; Jiawei Xie; Tiekun Ma
Journal:  J Nucl Med       Date:  2005-09       Impact factor: 10.057

3.  Isoelectric focusing and immunoblotting analysis of thyroglobulin from different thyroid diseases.

Authors:  A Olivieri; A Marzullo; G B Salabé; E Gilardi; C Fazzini; S Carta
Journal:  Thyroidology       Date:  1991-01

4.  Immunological cross reactivity between Candida albicans and human tissue.

Authors:  A Vojdani; P Rahimian; H Kalhor; E Mordechai
Journal:  J Clin Lab Immunol       Date:  1996

5.  ret/PTC-1 Activation in Hashimoto Thyroiditis.

Authors:  O. M. Sheils; J.J. O'eary; V. Uhlmann; K. Lättich; E. C. Sweeney
Journal:  Int J Surg Pathol       Date:  2000-07       Impact factor: 1.271

6.  High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations.

Authors:  J Hammer; C Belunis; D Bolin; J Papadopoulos; R Walsky; J Higelin; W Danho; F Sinigaglia; Z A Nagy
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

Review 7.  Infection, thyroid disease, and autoimmunity.

Authors:  Y Tomer; T F Davies
Journal:  Endocr Rev       Date:  1993-02       Impact factor: 19.871

8.  Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission.

Authors:  Laura Fugazzola; Alessandra Mihalich; Luca Persani; Nadia Cerutti; Michela Reina; Marco Bonomi; Emanuela Ponti; Deborah Mannavola; Enza Giammona; Guia Vannucchi; Anna Maria di Blasio; Paolo Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

Review 9.  The role of apoptosis in thyroid disease.

Authors:  A Tsatsoulis
Journal:  Minerva Med       Date:  2002-06       Impact factor: 4.806

10.  Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood.

Authors:  M D Ringel; P W Ladenson; M A Levine
Journal:  J Clin Endocrinol Metab       Date:  1998-12       Impact factor: 5.958

View more
  6 in total

1.  Thyroglobulin antibody resolution after total thyroidectomy for cancer.

Authors:  Jimmy Xu; Ryan Bergren; David Schneider; Herbert Chen; Rebecca S Sippel
Journal:  J Surg Res       Date:  2015-04-02       Impact factor: 2.192

Review 2.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

3.  Meta-analysis of radiofrequency ablation for treating the local recurrence of thyroid cancers.

Authors:  Q Zhao; G Tian; D Kong; T Jiang
Journal:  J Endocrinol Invest       Date:  2016-03-15       Impact factor: 4.256

4.  Long-term survival in a patient with brain metastases of papillary thyroid carcinoma.

Authors:  Daniela Guelho; Cristina Ribeiro; Miguel Melo; Francisco Carrilho
Journal:  BMJ Case Rep       Date:  2016-03-09

Review 5.  Approach to follow-up of the patient with differentiated thyroid cancer and positive anti-thyroglobulin antibodies.

Authors:  Matthew D Ringel; Fadi Nabhan
Journal:  J Clin Endocrinol Metab       Date:  2013-08       Impact factor: 5.958

6.  Dynamics of serum antithyroglobulin antibodies in patients with differentiated thyroid cancer.

Authors:  Fernanda Bueno; María Gabriela García Falcone; Mirna Angela Peñaloza; Erika Abelleira; Fabián Pitoia
Journal:  Endocrine       Date:  2019-10-24       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.